Health

Is MEDVi the Best GLP-1 Supplier for 2026? Platform Lists Compounded Semaglutide at $179/Month With No Contract Ahead of Weight Loss Season

Los Angeles, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Important Information for Readers: This article is for informational purposes only and…

6 months ago

Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC

SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC:…

6 months ago

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, ALK (ALKB:DC / OMX: ALK B) hereby announces that Arbejdsmarkedets…

6 months ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 19, 2025 16:15 ET  | Source: Zenas BioPharma WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc.…

6 months ago

Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes

ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced…

6 months ago

Is SkinnyRx the Best GLP-1 Vendor for 2026? Platform Offers Compounded Semaglutide in Three Forms Starting at $199/Month as New Year Weight Loss Season Approaches

Sacramento, Dec. 18, 2025 (GLOBE NEWSWIRE) -- With the New Year fast approaching and consumer interest in weight loss solutions…

6 months ago

Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

December 18, 2025 19:00 ET  | Source: Mesa Laboratories, Inc. LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories,…

6 months ago

Sequana Medical Announces Granting of Key Additional U.S. Patent for DSR

Ghent, Belgium, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Builds upon existing granted DSR patents in US, Europe, Japan and ChinaStrengthens…

6 months ago

InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

December 17, 2025 20:48 ET  | Source: InnoCare Pharma BEIJING, Dec. 17, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969;…

6 months ago

Sapu BioScience Highlights TGFB2-Guided Strategy to Enhance Taxane Therapies, Reinforcing the Rationale for Sapu-001

San Diego, CA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sapu BioScience today announced the publication of a new peer-reviewed study…

6 months ago